Otsuka Beijing Research Institute
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2003-08-29
- Employees
- -
- Market Cap
- -
- Website
- http://www.obri.com.cn
Clinical Trials
36
Active:2
Completed:33
Trial Phases
5 Phases
Phase 1:10
Phase 2:5
Phase 3:12
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Phase 3
12 (33.3%)Phase 1
10 (27.8%)Not Applicable
5 (13.9%)Phase 2
5 (13.9%)Phase 4
4 (11.1%)a Phase I PK Study in Healthy Male Subjects. 2 Groups of Healthy Male Subjects
Not Applicable
Completed
- Conditions
- Health Subjects
- Interventions
- Drug: singe dose 15mgDrug: multi dose 30mgDrug: single dose 30mgDrug: multi dose 60mgDrug: single dose 60mgDrug: single dose 120mg
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 64
- Registration Number
- NCT07166796
Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT07166783
Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT07166887
Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT07105124
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
Phase 1
Active, not recruiting
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06091267
- Locations
- 🇨🇳
The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found